Genmab
GMAB
217 hedge funds and large institutions have $1.62B invested in Genmab in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 74 increasing their positions, 94 reducing their positions, and 42 closing their positions.
53% more call options, than puts
Call options by funds: $6.37M | Put options by funds: $4.18M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.29% less ownership
Funds ownership: 69.33% → 66.04% (-3.3%)
8% less funds holding
Funds holding: 237 → 217 (-20)
16% less capital invested
Capital invested by funds: $1.94B → $1.62B (-$318M)
21% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 94
38% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$22.5M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$16.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$13.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10M |
| 5 |
Jane Street
New York
|
+$7.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$28.5M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$27.4M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$24.8M |
| 4 |
Millennium Management
New York
|
-$23.6M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$20.4M |
GMAB Hedge Fund Activity: Q1 2023 in Review
217 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2023, worth a combined $1.62B — down 16% from $1.94B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of GMAB and 26 opened new positions — a net loss of 16 holders — while 94 trimmed existing stakes and 74 added.
The largest buyer was Envestnet Asset Management, adding an estimated $22.5M. The largest seller was Arrowstreet Capital, cutting an estimated $28.5M.
- 217 institutional investors held Genmab (GMAB) as of Q1 2023, down from 237 in Q4 2022.
- Funds reported $1.62B of Genmab stock for Q1 2023, down 16% quarter-over-quarter.
- 26 funds opened new Genmab positions in Q1 2023 and 42 closed out, a net change of -16 holders.
- The largest Genmab buyer in Q1 2023 was Envestnet Asset Management, an estimated $22.5M added.
- The largest Genmab seller in Q1 2023 was Arrowstreet Capital, an estimated $28.5M sold.
Based on aggregated 13F filings for Q1 2023.